A therapeutic study in pre-ICU patients admitted with coronavirus using repurposed drugs
| ISRCTN | ISRCTN11188345 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN11188345 |
| ClinicalTrials.gov (NCT) | NCT04390464 |
| Clinical Trials Information System (CTIS) | 2020-001354-22 |
| Integrated Research Application System (IRAS) | 282213 |
| Protocol serial number | CCTU0303; IRAS 282213 |
| Sponsor | Cambridge University Hospitals NHS Foundation Trust |
| Funders | Eli Lilly and Company, Alexion Pharmaceuticals |
- Submission date
- 15/05/2020
- Registration date
- 15/05/2020
- Last edited
- 05/03/2024
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Plain English summary of protocol
Background and study aims
COVID-19 is a condition caused by the coronavirus (called SARS-CoV-2) that was first identified in late 2019. This virus can infect the respiratory (breathing) system. Some people do not have symptoms but can carry the virus and pass it on to others. People who have developed the condition may develop a fever and/or a continuous cough among other symptoms. This can develop into pneumonia. Pneumonia is a chest infection where the small air pockets of the lungs, called alveoli, fill with liquid and make it more difficult to breathe.
In 2020, the virus has spread to many countries around the world and neither a vaccine against the virus or specific treatment for COVID-19 has yet been developed. As of March 2020, it is advised that people minimize travel and social contact, and regularly wash their hands to reduce the spread of the virus.
Groups who are at a higher risk from infection with the virus, and therefore of developing COVID-19, include people aged over 70 years, people who have long-term health conditions (such as asthma or diabetes), people who have a weakened immune system and people who are pregnant. People in these groups, and people who might come into contact with them, can reduce this risk by following the up-to-date advice to reduce the spread of the virus.
Current knowledge about severe COVID-19 related disease suggests that patients develop an over activation of their immune system in response to the infection, which may lead to organ. Several medications licensed for patients with autoimmune disease can be used to prevent such over activation of the immune response.
This trial plans to recruit patients at an early stage in the disease course, around early infection and when the patient is starting to show mild lung complications. The purpose is to prevent organ damage and reduce the need to transfer patients to ICU and for ventilated breathing support.
Who can participate?
Adults over 18 years, strongly suspected to have a COVID-19 related disease (with or without a positive COVID-19 test), who are suitable candidates for the intervention.
What does the study involve?
Participants will be randomly allocated to receive Baricitinib in addition to standard of care, or Ravulizumab in addition to standard of care, or standard of care only. Participants will be monitored for up to 14 days with follow up visits at day 28 and day 90 after the first dosing visit.
What are the possible benefits and risks of participating?
There are no known benefits of participating in this trial.
The effect of the drugs will be analysed during the trial to make efficient decisions about efficacy and futility (e.g. lack of efficacy and risk of harm) of the trial treatments. This enables us to stop recruiting if any serious risks arise.
Where is the study run from?
Addenbrookes Hospital (UK)
When is the study starting and how long is it expected to run for?
May 2020 to October 2021
Who is funding the study?
1. Eli Lilly and Company UK Ltd.
2. Alexion Pharmaceuticals UK
Who is the main contact?
Unfortunately, this study is not recruiting public volunteers at this time. This is because the research isn’t ready for volunteers yet or the researchers are directly identifying volunteers in certain areas or hospitals. Please do not contact the research team as they will not be able to respond. For more information about COVID-19 research, visit the Be Part of Research homepage (https://bepartofresearch.nihr.ac.uk/).
Contact information
Scientific
Cambridge University Hospitals NHS Trust/Univ of Cambridge
Box 110, Level 3
ACCI Building
Cambridge University Hospitals NHS FT
Hills Rd
Cambridge
CB2 0QQ
United Kingdom
 ORCID ID |
0000-0001-6921-1592 |
|---|---|
| Phone | +44 (0)1223 336517 |
| eh560@medschl.cam.ac.uk |
Public
Cambridge Clinical Trials Unit
Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital
Cambridge
CB2 0QQ
United Kingdom
| Phone | +44 (0)1223 349132 |
|---|---|
| cuh.cctu@nhs.net |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomized parallel arm open-label multicentre Phase IV platform trial |
| Secondary study design | Randomised parallel trial |
| Study type | Participant information sheet |
| Scientific title | mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R) |
| Study acronym | TACTIC-R |
| Study objectives | 1. Immune modulatory therapy is superior to standard of care alone 2. Reduction of exaggerated host immune response to COVID-19 in patients at late stage 1/early stage 2 disease, reduces the composite of progression of these patients to organ failure or death and also reduces late sequelae of infection 3. Clinical and biochemical markers can be used to stratify each patient to an effective therapeutic agent and can report early on efficacy of the therapeutic approach |
| Ethics approval(s) | Approved 04/05/2020, East of England - Cambridge Central Research Ethics Committee (Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)207 104 8388; cambridgecentral.rec@hra.nhs.uk), ref: 20/EE/0135 |
| Health condition(s) or problem(s) studied | Late stage 1/stage 2 COVID-19-related disease, COVID-19 (SARS-CoV-2 infection) |
| Intervention | Eligible patients will be randomised to receive 1:1:1 to one of the following treatment arms (each in addition to standard of care (SoC)) Arm 1: Baricitinib oral tablets (4mg OD) in addition to standard of care Arm 2: Ravulizumab intravenous infusion (single dose, weight-based dosing) in addition to standard of care Arm 3: Standard of care Randomisation will be carried out using a validated central automated web-based randomisation system. Arm 1 Participants will be given 4mg of Baricitinib PO (2 x 2mg tables, once daily) on days 1-14 PO. Dose adjustments for age and renal function. Arm 2 Participants will receive Ravulizumab as a single intravenous infusion, Ravulizumab weight-based dosing regimen: Body weight range (kg) Dose (mg) ≥ 40 to < 60 2,400 ≥ 60 to < 100 2,700 ≥ 100 3,000 Duration of follow up: There will be two follow up visits at day 28 and day 90 after the first dosing visit. Assessments will include the following: • Discharge status • Vaccination status (for ravulizumab arm only) • Return to normal function status (numeric rating scale 0-10) • Mortality status • Adverse event reporting • ECOG and MRC scores |
| Intervention type | Drug |
| Phase | Phase IV |
| Drug / device / biological / vaccine name(s) | Baricitinib, ravulizumab |
| Primary outcome measure(s) |
Time to incidence (up to Day 14) of the composite endpoint of: |
| Key secondary outcome measure(s) |
Measured using patient records: |
| Completion date | 01/10/2021 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 375 |
| Total final enrolment | 417 |
| Key inclusion criteria | 1. Be aged 18 years and over 2. Have clinical picture strongly suggestive of COVID-19-related disease (with/without positive COVID-19 test) AND 2.1. Risk count (as defined above) >3 OR 2.3. Risk count 3 if risk count includes “Radiographic severity score >3” 3. Be considered an appropriate subject for intervention with immunomodulatory in the opinion of the investigator 4. Be able to be maintained on venous thromboembolism prophylaxis or current maintenance therapy during inpatient dosing period, according to local guidelines |
| Key exclusion criteria | 1. Inability to supply direct informed consent from patient or from Next of Kin or Independent Healthcare Provider on behalf of patient 2. Mechanical ventilation at time of prior to dosing 3. Contraindications to study drugs, including hypersensitivity to the active substances or any of the excipients 4. Currently on any of the study investigational medicinal products 5. Known unresolved Neisseria meningitidis infection 6. Unwilling to be vaccinated against Neisseria meningitidis or receive prophylactic antibiotic cover until 2 weeks after vaccination 7. Known active tuberculosis (no blood screening required) 8. Known active Hepatitis B or C (no blood screening required); active varicella zoster. 9. Concurrent participation in any interventional clinical trial including COVID-19-related disease trials (observational studies allowed) 10. Patient moribund at presentation or screening 11. Pregnancy at screening (or unwillingness to adhere to pregnancy advice in protocol) 12. Unwillingness to adhere to breastfeeding advice in protocol. 13. Either alanine transaminase or aspartate transaminase (ALT or AST) > 5 times the upper limit of normal 14. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. Cockcroft Gault estimated creatinine clearance < 30 ml /min/1.73 m2) 15. Currently receiving probenecid or chronic IVIG treatment 16. Any medical history or clinically relevant abnormality that is deemed by the principal investigator and/or medical monitor to make the patient ineligible for inclusion because of a safety concern |
| Date of first enrolment | 07/05/2020 |
| Date of final enrolment | 22/06/2021 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centres
Hills Road
Cambridge
CB2 0QQ
United Kingdom
Denmark Hill
London
SE5 9RS
United Kingdom
Great Maze Pond
London
SE1 9RT
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | Yes |
|---|---|
| IPD sharing plan summary | Available on request |
| IPD sharing plan | Full individual participant data (deidentified) will be available to researchers who provide a methodologically sound proposal, available for 24 months after publication of the trial. Proposals should be directed to Dr Frances C Hall (fch22@medschl.cam.ac.uk). Data requestors will need to sign a data access agreement. Data will be shared via a secure data access system. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | 14/11/2023 | 05/03/2024 | Yes | No | |
| Protocol article | protocol | 08/07/2020 | 10/07/2020 | Yes | No |
| HRA research summary | 28/06/2023 | No | No | ||
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
| Study website | Study website | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
05/03/2024: Publication reference and IPD sharing statement added.
26/05/2023: Contact details updated.
07/09/2021: The overall trial end date was changed from 01/09/2021 to 01/10/2021.
30/07/2021: The following changes were made to the trial record:
1. The overall end date was changed from 01/05/2022 to 01/09/2021.
2. The recruitment end date was changed from 01/07/2021 to 22/06/2021.
3. The total final enrolment was added.
4. The plain English summary was updated to reflect these changes.
03/11/2020: The recruitment end date was changed from 07/11/2020 to 01/07/2021.
10/07/2020: Publication reference added.
20/05/2020: Internal review.
15/05/2020: Trial’s existence confirmed by National Institute for Health Research (NIHR).
